Mostrar el registro sencillo del ítem

dc.contributor.authorRyan, Pablo
dc.contributor.authorValencia, Jorge
dc.contributor.authorCuevas, Guillermo
dc.contributor.authorTorres-Macho, Juan
dc.contributor.authorTroya, Jesús
dc.contributor.authorPueyo, Ángel
dc.contributor.authorMuñoz-Gómez, María José 
dc.contributor.authorMuñoz-Rivas, Nuria
dc.contributor.authorVázquez-Morón, Sonia 
dc.contributor.authorMartinez, Isidoro 
dc.contributor.authorLazarus, Jeffrey V
dc.contributor.authorResino, Salvador 
dc.date.accessioned2024-05-22T08:42:58Z
dc.date.available2024-05-22T08:42:58Z
dc.date.issued2021-10
dc.identifier.citationInt J Drug Policy. 2021 Oct:96:103424.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/19518
dc.description.abstractBackground: The burden of hepatitis C virus (HCV) infection among marginalized people in Spain is high, despite the fact that HCV prevalence has decreased in recent years. We aimed to assess the effectiveness of a simplified point-of-care (PoC) model for screening for active HCV infection via a mobile unit and subsequent linkage to care with the assistance of navigators. Methods: We carried out a prospective study on 2001 participants from Madrid, Spain. A nurse and a navigator/educator screened for hepatitis C in a mobile unit, using the OraQuick HCV Rapid Antibody Test and Xpert HCV VL Fingerstick assay. Participants with active HCV were referred to the hospital the same day with a navigator for evaluation and treatment of HCV. Results: Overall, 1621 (81%) participants had not been exposed to HCV, 380 (18.9%) were positive for HCV antibodies, and 136 (6.8%) had active hepatitis C. Among the latter, 134 (98.5%) received the HCV screening results, 133 (97.8%) had an appointment at the hospital, 126 (92.8%) were seen by a physician once they were at the hospital, and 105 (77.2%) started HCV treatment. Being over 50 years old and a person who uses drugs, particularly people who inject drugs (PWID), was directly associated with active hepatitis C (p<0.05). PWID were the only patients with HCV reinfection (4.3% in people without recent injecting drug use and 5.9% in people with recent injecting drug use). Among PWID, no income and daily alcohol intake were also directly associated with active hepatitis C. People with recent injecting drug use showed the lowest rates of attendance at the hospital (91.8%) and starting HCV treatment (70.4%). Conclusion: HCV screening using a two-step PoC-based strategy and its linkage to care was extremely efficient for identifying and treating marginalized people with active hepatitis C, thanks to the use of a mobile unit with personnel and technical equipment, an interdisciplinary team, and collaboration between institutions.es_ES
dc.description.sponsorshipThis work was funded by a research grant from Gilead Science (IN-ES-987-5391 and GLD20_0144) and Instituto de Salud Carlos III (ISCII; grant numbers PI20CIII/00004 and RD16CIII/0002/0002 to SR). It also received funding from AbbVie, Asociación Española para Estudio del Higado (AEEH), and Madrid Positivo Association.es_ES
dc.language.isoenges_ES
dc.publisherElsevier es_ES
dc.type.hasVersionSMURes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectHepatitis Ces_ES
dc.subjectScreening mobile unites_ES
dc.subjectPeople who use drugses_ES
dc.subjectPoint-of-carees_ES
dc.subjectLinkage-to-carees_ES
dc.subjectHCV testinges_ES
dc.subjectHCV treatmentes_ES
dc.subjectSpaines_ES
dc.subject.meshHepatitis C es_ES
dc.subject.meshSubstance Abuse, Intravenouses_ES
dc.subject.meshAntiviral Agents es_ES
dc.subject.meshHepacivirus es_ES
dc.subject.meshHepatitis C Antibodies es_ES
dc.subject.meshHumans es_ES
dc.subject.meshMiddle Aged es_ES
dc.subject.meshProspective Studies es_ES
dc.subject.meshSpain es_ES
dc.titleDetection of active hepatitis C in a single visit and linkage to care among marginalized people using a mobile unit in Madrid, Spaines_ES
dc.typeresearch articlees_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.identifier.pubmedID34429222es_ES
dc.format.volume96es_ES
dc.format.page103424es_ES
dc.identifier.doi10.1016/j.drugpo.2021.103424es_ES
dc.contributor.funderGilead Sciences (Spain) es_ES
dc.contributor.funderInstituto de Salud Carlos III es_ES
dc.contributor.funderAbbVie es_ES
dc.contributor.funderAsociación Española para Estudio del Higado (AEEH)es_ES
dc.contributor.funderMadrid Positivo Associationes_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1873-4758es_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.drugpo.2021.103424es_ES
dc.identifier.journalThe International journal on drug policyes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.relation.projectFISinfo:fis/Instituto de Salud Carlos III/Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I/Subprograma Estatal de Generación de Conocimiento/PI20-ISCIII Modalidad Proyectos de Investigacion en Salud Intramurales. (2020)/PI20CIII/00004es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/RD16CIII/0002/0002es_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 Internacional